I
Ira Oliff
Researcher at University of Arizona
Publications - 4
Citations - 1874
Ira Oliff is an academic researcher from University of Arizona. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 2, co-authored 3 publications receiving 1820 citations.
Papers
More filters
Journal ArticleDOI
Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
Roy S. Herbst,Giuseppe Giaccone,Joan H. Schiller,Ronald B. Natale,Vincent A. Miller,Christian Manegold,Giorgio V. Scagliotti,Rafael Rosell,Ira Oliff,James A. Reeves,Michael K. Wolf,Annetta D. Krebs,Steven D. Averbuch,Judith S. Ochs,John Grous,Abderrahim Fandi,David H. Johnson +16 more
TL;DR: This large, placebo-controlled trial confirmed the favorable gefitinib safety profile observed in phase I and II monotherapy trials and showed no added benefit in survival, time to progression, response rate (TTP), or RR compared with standard chemotherapy alone.
Journal ArticleDOI
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB–Expressing Breast Cancer
Denise A. Yardley,Robert Weaver,Michelle E. Melisko,Mansoor N. Saleh,Francis P. Arena,Andres Forero,Tessa Cigler,Alison Stopeck,Dennis Citrin,Ira Oliff,Rebecca Bechhold,Randa Loutfi,Agustin A. Garcia,Scott Cruickshank,Elizabeth Crowley,Jennifer Green,Thomas Hawthorne,Michael Yellin,Thomas A. Davis,Linda T. Vahdat +19 more
TL;DR: Glembatumumab vedotin was well tolerated as compared with IC chemotherapy (less hematologic toxicity; more rash, pruritus, neuropathy, and alopecia), and activity may be enhanced in patients with gpNMB-overexpressing tumors and/or TNBC.
Journal ArticleDOI
RX 3117: Activity of an oral antimetabolite nucleoside in subjects with pancreatic cancer–Preliminary results of stage II of the phase Ia/IIb study.
Vincent Chung,Jaime R. Merchan,Allyson J. Ocean,Drew W. Rasco,Hani M. Babiker,Ira Oliff,Ravi Kumar Paluri,Eloy Roman,Julie Poore,Ely Benaim +9 more
TL;DR: Data from stage 2 of the Phase 1b/2a clinical study of RX3117 as a single agent in subjects with metastatic pancreatic cancer, which evaluated safety, tolerability and efficacy following treatment, is described below.
Journal ArticleDOI
Isolated Enteric Myeloid Sarcoma as a Rare Etiology of Small Bowel Obstruction in a Young Female Patient
TL;DR: A case of isolated enteric MS is described, which was associated with a rare MYH11/CBFB fusion and inversion 16 chromosomal aberration which is rarely associated with myeloid disorders.